New York Cannabis Hits $3.3 Billion With 600+ Dispensaries: The MRTA at Five Years

Five years ago, New York Governor Kathy Hochul signed the Marihuana Regulation and Taxation Act into law, promising that the Empire State would build a cannabis market that was not only commercially viable but fundamentally different from the ones that came before it. The MRTA didn't just legalize cannabis — it attempted to embed social equity, criminal justice reform, and community reinvestment into the DNA of the industry from day one.

In March 2026, Governor Hochul marked the five-year anniversary with numbers that would have seemed ambitious even by the most optimistic projections: $3.3 billion in total retail sales, more than 600 licensed dispensaries statewide, and 2,161 adult-use cannabis licenses issued. Pure Blossom, on Manhattan's Upper West Side, was recognized as the state's 600th licensed retail location.

The numbers are impressive. But the story behind them — who got those licenses, who's making money, and what remains unfinished — is where New York's cannabis experiment gets genuinely interesting.

The Equity Scorecard

The MRTA's most ambitious promise was that the communities most harmed by cannabis prohibition would be the first to benefit from legalization. Five years in, the numbers suggest that promise has been at least partially kept.

Fifty-six percent of adult-use cannabis licenses across the supply chain have been awarded to Social and Economic Equity (SEE) applicants — individuals from communities disproportionately impacted by marijuana enforcement, people with prior cannabis convictions, and members of economically disadvantaged groups. That figure exceeds the state's own statutory goals.

Within those equity licenses, 57 percent have gone to women-owned businesses and 51 percent to minority-owned businesses. These are not token numbers. In an industry where national statistics consistently show white males dominating ownership, New York's licensing demographics represent a genuine departure from the norm.

Governor Hochul's 2026 State of the State address included a $17 million investment to expand SEE initiatives and programming — funding for technical assistance, business incubation, and the kind of operational support that can mean the difference between a license holder who opens a successful business and one whose license sits unused.

The Criminal Justice Dimension

The MRTA's criminal justice provisions have had measurable impact. More than 400,000 marijuana-related convictions are eligible for expungement under the law, and over 200,000 have been sealed to date. For the individuals affected — people who may have been carrying the weight of a cannabis conviction for decades, affecting their employment, housing, and educational opportunities — these are life-changing legal reforms.

The expungement provisions work automatically in many cases, meaning affected individuals don't need to hire a lawyer or navigate a complex petition process. The state's Unified Court System identifies eligible records and processes the sealing, a design choice that removes barriers that have historically prevented people from accessing the relief they're entitled to.

Where the Money Is Going

New York's cannabis tax revenue is structured to flow into three dedicated funds. The first supports public education. The second funds community grants in neighborhoods most impacted by the war on drugs. The third supports drug treatment and public education programs.

The state has also established the Cannabis Social Equity Investment Fund, designed to provide startup capital, real estate assistance, and technical support to equity licensees. The fund acknowledges a reality that other states learned the hard way: giving someone a cannabis license without providing the capital and expertise to actually operate a cannabis business is a recipe for equity in name only.

The Challenges That Remain

The numbers don't tell the whole story, and there are genuine criticisms of New York's cannabis rollout that deserve acknowledgment.

The illicit market is still massive. Despite 600-plus legal dispensaries, estimates suggest that the unlicensed market still controls a significant share of cannabis sales in New York, particularly in New York City. Unlicensed shops — many operating in plain sight, with flashy storefronts and aggressive marketing — undercut licensed retailers on price because they don't pay taxes, don't test their products, and don't comply with the regulatory requirements that add cost to legal operations.

The Office of Cannabis Management has ramped up enforcement, but shutting down unlicensed operators has proven to be a game of whack-a-mole. Many reopen within days of being closed, sometimes at the same location.

Equity licensees face real operational challenges. Having a license is not the same as having a thriving business. Many equity licensees have struggled with access to banking, real estate, and supply chain logistics — the same systemic barriers that prompted the equity provisions in the first place. The $17 million investment in SEE programming is a step toward addressing these gaps, but advocates argue that significantly more support is needed to ensure equity licensees can compete with better-capitalized operators.

Regulatory complexity is a drag on growth. New York's cannabis regulations are extensive, and compliance costs are substantial. Smaller operators — disproportionately equity licensees — bear these costs more heavily than larger, better-funded competitors. Streamlining the regulatory framework without sacrificing consumer safety is an ongoing challenge.

How New York Compares

Among the states that have legalized adult-use cannabis, New York's approach is distinctive in several ways. It has the most aggressive social equity provisions of any major cannabis market. Its licensing has produced the most diverse ownership demographics in the country. And its criminal justice provisions — automatic expungement, record sealing — are among the most progressive.

At the same time, New York was slower to launch its legal market than states like Illinois, Michigan, or Massachusetts, and the persistent illicit market problem suggests that the regulatory and tax structures may still need adjustment.

The $3.3 billion in total retail sales puts New York among the top cannabis markets in the country, though on a per-capita basis it still trails states like Colorado and Oregon that have had legal sales for much longer. The trajectory is upward, but the market hasn't fully matured.

Five Years In, Looking Forward

The MRTA was always designed as a long-term experiment — an attempt to prove that a cannabis market could be built on principles of equity and justice without sacrificing commercial viability. Five years in, the experiment is producing mixed but generally encouraging results.

The equity numbers are real. The criminal justice impact is real. The revenue is real. The problems — the illicit market, the operational challenges facing small operators, the regulatory complexity — are also real. New York's cannabis market isn't a finished product. It's a work in progress, and the next five years will determine whether the ambitious promises of the MRTA translate into lasting, structural change.

Six hundred dispensaries in five years, in a state that spent decades debating whether to legalize at all, is a meaningful accomplishment. But the real measure of success isn't how many dispensaries opened — it's whether the people those dispensaries were meant to serve are actually benefiting. On that question, the jury is still deliberating.

Ready to find a licensed shop near you? Browse New York dispensaries and Budpedia's full directory of verified cannabis dispensaries.